Oculis Reports Q1 2025 Financial Results and Provides Company Update

R&D Day Key Highlights: Recent Clinical Highlights and Upcoming Milestones: The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic Neuritis OCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the firs ...